{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T17:43:28Z","timestamp":1791222208909,"version":"4.1.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T00:00:00Z","timestamp":1645401600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T00:00:00Z","timestamp":1645401600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer"],"published-print":{"date-parts":[[2022,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      In 2018, BRACAnalysis\u00ae was covered by medical insurance in Japan as a companion diagnostic test for the poly ADP-ribose polymerase inhibitor olaparib. In April 2020, eligibility for\n                      <jats:italic>BRCA1\/2<\/jats:italic>\n                      genetic testing was expanded to the diagnosis of hereditary breast and ovarian cancer syndrome, and medical management including prophylactic surgery and surveillance were covered by public insurance for\n                      <jats:italic>BRCA1\/2<\/jats:italic>\n                      mutation carriers who developed breast or ovarian cancer. The amount of\n                      <jats:italic>BRCA1\/2<\/jats:italic>\n                      genetic testing has been increasing recently, but the number of subjects and the impact of testing for patients\u2019 outcomes remain unclear.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and methods<\/jats:title>\n                    <jats:p>\n                      This study explored the potential number of patients who will be eligible for new insurance coverage for\n                      <jats:italic>BRCA1\/2<\/jats:italic>\n                      genetic testing. We analyzed 868 patients from 938 surgeries between January 2014 and September 2020 from our database.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Overall, 372 patients (43%) were eligible for new insurance coverage for\n                      <jats:italic>BRCA1\/2<\/jats:italic>\n                      genetic testing. The most common category was family history of breast or ovarian cancer within third-degree relatives. We found that 202 patients (23%) had family history of breast or ovarian cancer. In addition, the progression-free survival was significantly lower in triple-negative breast cancer patients aged 60\u00a0years or younger compared with the other patients (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.0005).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      The genetic medicine for primary breast cancer patients with\n                      <jats:italic>BRCA1\/2<\/jats:italic>\n                      germline mutation is accelerating rapidly in Japan. Therefore, establishing a system for the genetic medicine would be urgent.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s12282-022-01342-4","type":"journal-article","created":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T13:12:20Z","timestamp":1645449140000},"page":"659-665","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Genetic medicine is accelerating in Japan"],"prefix":"10.1007","volume":"29","author":[{"given":"Saori","family":"Hayashi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Kubo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhisa","family":"Kaneshiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaya","family":"Kai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mai","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takafumi","family":"Morisaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuka","family":"Takao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akiko","family":"Shimazaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sawako","family":"Shikada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masafumi","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,2,21]]},"reference":[{"key":"1342_CR1","doi-asserted-by":"publisher","first-page":"e48","DOI":"10.1016\/j.clbc.2020.08.004","volume":"21","author":"M Inuzuka","year":"2021","unstructured":"Inuzuka M, Watanabe C, Yokoyama S, Kuwayama T, Akashi-Tanaka S, Arai M, et al. A retrospective analysis of the relationship between the result of BRCA1\/2 genetic testing and surgical method selection in Japan. Clin Breast Cancer. 2021;21:e48-52.","journal-title":"Clin Breast Cancer"},{"key":"1342_CR2","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1038\/s10038-017-0355-1","volume":"63","author":"M Arai","year":"2018","unstructured":"Arai M, Yokoyama S, Watanabe C, Yoshida R, Kita M, Okawa M, et al. Genetic and clinical characteristics in Japanese hereditary breast and ovarian cancer: first report after establishment of HBOC registration system in Japan. J Hum Genet. 2018;63:447\u201357.","journal-title":"J Hum Genet"},{"key":"1342_CR3","doi-asserted-by":"publisher","first-page":"e1217","DOI":"10.1016\/j.clbc.2018.05.008","volume":"18","author":"H Mori","year":"2018","unstructured":"Mori H, Kubo M, Kai M, Velasquez VV, Kurata K, Yamada M, et al. BRCAness combined with a family history of cancer is associated with a poor prognosis for breast cancer patients with a high risk of BRCA mutations. Clin Breast Cancer. 2018;18:e1217\u201327.","journal-title":"Clin Breast Cancer"},{"key":"1342_CR4","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1126\/science.7545954","volume":"266","author":"Y Miki","year":"1994","unstructured":"Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science. 1994;266:66\u201371.","journal-title":"Science"},{"key":"1342_CR5","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1038\/s41588-020-0609-2","volume":"52","author":"H Zhang","year":"2020","unstructured":"Zhang H, Ahearn TU, Lecarpentier J, Barnes D, Beesley J, Qi G, et al. Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses. Nat Genet. 2020;52:572\u201381.","journal-title":"Nat Genet"},{"issue":"11","key":"1342_CR6","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1111\/j.1349-7006.2004.tb02195.x","volume":"95","author":"K Yoshida","year":"2004","unstructured":"Yoshida K, Miki Y. Role of BRCA1 and BRCA2 as regulators of DNA repair, transcription, and cell cycle in response to DNA damage. Cancer Sci. 2004;95(11):866\u201371.","journal-title":"Cancer Sci"},{"key":"1342_CR7","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1056\/NEJMoa1706450","volume":"377","author":"M Robson","year":"2017","unstructured":"Robson M, Im S-A, Senkus E, Xu B, Domchek SM, Masuda N, et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med. 2017;377:523\u201333.","journal-title":"N Engl J Med"},{"key":"1342_CR8","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/S1470-2045(17)30891-4","volume":"19","author":"ER Copson","year":"2018","unstructured":"Copson ER, Maishman TC, Tapper WJ, Cutress RI, Greville-Heygate S, Altman DG, et al. Germline BRCA mutation and outcome in young-onset breast cancer (POSH): a prospective cohort study. Lancet Oncol. 2018;19:169\u201380.","journal-title":"Lancet Oncol"},{"key":"1342_CR9","doi-asserted-by":"publisher","first-page":"e1229","DOI":"10.1016\/j.clbc.2017.12.014","volume":"18","author":"S Yadav","year":"2018","unstructured":"Yadav S, Ladkany R, Yadav D, Alhalabi O, Khaddam S, Isaac D, et al. Impact of BRCA mutation status on survival of women with triple-negative breast cancer. Clin Breast Cancer. 2018;18:e1229\u201335.","journal-title":"Clin Breast Cancer"},{"key":"1342_CR10","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1200\/JCO.2013.53.6607","volume":"32","author":"AW Kurian","year":"2014","unstructured":"Kurian AW, Hare EE, Mills MA, Kingham KE, McPherson L, Whittemore AS, et al. Clinical evaluation of a multiple-gene sequencing panel for hereditary cancer risk assessment. J Clin Oncol. 2014;32:2001\u20139.","journal-title":"J Clin Oncol"},{"key":"1342_CR11","unstructured":"https:\/\/www.astrazeneca.co.jp\/media\/press-releases1\/2018\/2018070204.html#! [cited 2021 Jan 8]"},{"key":"1342_CR12","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1093\/annonc\/mdz136","volume":"30","author":"D Mandelker","year":"2019","unstructured":"Mandelker D, Donoghue M, Talukdar S, Bandlamudi C, Srinivasan P, Vivek M, et al. Germline-focussed analysis of tumour-only sequencing: recommendations from the ESMO Precision Medicine Working Group. Ann Oncol. 2019;30:1221\u201331.","journal-title":"Ann Oncol"},{"key":"1342_CR13","doi-asserted-by":"publisher","first-page":"e1361","DOI":"10.1016\/j.clbc.2018.07.015","volume":"18","author":"M D\u2019Alonzo","year":"2018","unstructured":"D\u2019Alonzo M, Piva E, Pecchio S, Liberale V, Modaffari P, Ponzone R, et al. Satisfaction and impact on quality of life of clinical and instrumental surveillance and prophylactic surgery in BRCA-mutation carriers. Clin Breast Cancer. 2018;18:e1361\u20136.","journal-title":"Clin Breast Cancer"},{"key":"1342_CR14","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1007\/s10549-014-3134-0","volume":"148","author":"X Chai","year":"2014","unstructured":"Chai X, Friebel TM, Singer CF, Evans DG, Lynch HT, Isaacs C, et al. Use of risk-reducing surgeries in a prospective cohort of 1,499 BRCA1 and BRCA2 mutation carriers. Breast Cancer Res Treat. 2014;148:397\u2013406.","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"1342_CR15","doi-asserted-by":"publisher","first-page":"77","DOI":"10.6004\/jnccn.2021.0001","volume":"19","author":"MB Daly","year":"2021","unstructured":"Daly MB, Pal T, Berry MP, Buys SS, Dickson P, Domchek SM, et al. Genetic\/familial high-risk assessment: breast, ovarian, and pancreatic, version 2.2021. JNCCN J Natl Compr Cancer Netw. 2021;19(1):77\u2013102.","journal-title":"JNCCN J Natl Compr Cancer Netw"},{"key":"1342_CR16","doi-asserted-by":"publisher","first-page":"6113","DOI":"10.1158\/1078-0432.CCR-16-3227","volume":"23","author":"J Sun","year":"2017","unstructured":"Sun J, Meng H, Yao L, Lv M, Bai J, Zhang J, et al. Germline mutations in cancer susceptibility genes in a large series of unselected breast cancer patients. Clin Cancer Res. 2017;23:6113\u20139.","journal-title":"Clin Cancer Res"},{"key":"1342_CR17","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1158\/1078-0432.CCR-08-1822","volume":"15","author":"I Agalliu","year":"2009","unstructured":"Agalliu I, Gern R, Leanza S, Burk RD. Associations of high-grade prostate cancer with BRCA1 and BRCA2 founder mutations. Clin Cancer Res. 2009;15:1112\u201320.","journal-title":"Clin Cancer Res"},{"key":"1342_CR18","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1038\/gim.2017.85","volume":"20","author":"KG Chaffee","year":"2018","unstructured":"Chaffee KG, Oberg AL, McWilliams RR, Majithia N, Allen BA, Kidd J, et al. Prevalence of germ-line mutations in cancer genes among pancreatic cancer patients with a positive family history. Genet Med. 2018;20:119\u201327.","journal-title":"Genet Med"},{"key":"1342_CR19","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1056\/NEJMoa1903387","volume":"381","author":"T Golan","year":"2019","unstructured":"Golan T, Hammel P, Reni M, Van Cutsem E, Macarulla T, Hall MJ, et al. Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer. N Engl J Med. 2019;381:317\u201327.","journal-title":"N Engl J Med"},{"key":"1342_CR20","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1056\/NEJMoa1911440","volume":"382","author":"J de Bono","year":"2020","unstructured":"de Bono J, Mateo J, Fizazi K, Saad F, Shore N, Sandhu S, et al. Olaparib for metastatic castration-resistant prostate cancer. N Engl J Med. 2020;382:2091\u2013102.","journal-title":"N Engl J Med"},{"key":"1342_CR21","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1093\/annonc\/mdx362.065","volume":"28","author":"A Tutt","year":"2017","unstructured":"Tutt A, Kaufman B, Garber J, Gelber R, McFadden E, Goessl C, et al. OlympiA: a randomized phase III trial of olaparib as adjuvant therapy in patients with high-risk HER2-negative breast cancer (BC) and a germline BRCA1\/2 mutation (gBRCAm). Ann Oncol. 2017;28:67.","journal-title":"Ann Oncol"},{"key":"1342_CR22","unstructured":"https:\/\/www.astrazeneca.com\/media-centre\/press-releases\/2021\/olympia-trial-of-lynparza-idmc-recommend-early-analysis.html [cited 2021 Aug 28]"},{"key":"1342_CR23","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1001\/jama.2018.13152","volume":"320","author":"J Mersch","year":"2018","unstructured":"Mersch J, Brown N, Pirzadeh-Miller S, Mundt E, Cox HC, Brown K, et al. Prevalence of variant reclassification following hereditary cancer genetic testing. JAMA J Am Med Assoc. 2018;320:1266\u201374.","journal-title":"JAMA J Am Med Assoc"},{"key":"1342_CR24","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1200\/PO.20.00020","volume":"4","author":"L Esterling","year":"2020","unstructured":"Esterling L, Wijayatunge R, Brown K, Morris B, Hughes E, Pruss D, et al. Impact of a Cancer Gene Variant Reclassification Program Over a 20-Year Period. JCO Precis Oncol. 2020;4:944\u201354.","journal-title":"JCO Precis Oncol"},{"key":"1342_CR25","unstructured":"https:\/\/myriadgenetics.jp\/patients-families\/genetic-testing-101\/vus-importance\/ [cited 2021 Sep 30]"},{"key":"1342_CR26","first-page":"145","volume":"130","author":"LJ Lee","year":"2011","unstructured":"Lee LJ, Alexander B, Schnitt SJ, Comander A, Gallagher B, Garber JE, et al. Clinical outcome of triple negative breast cancer in BRCA1 mutation carriers and noncarriers. Cancer. 2011;130:145\u201353.","journal-title":"Cancer"},{"key":"1342_CR27","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s10549-011-1711-z","volume":"130","author":"S Bayraktar","year":"2011","unstructured":"Bayraktar S, Gutierrez-Barrera AM, Liu D, Tasbas T, Akar U, Litton JK, et al. Outcome of triple-negative breast cancer in patients with or without deleterious BRCA mutations. Breast Cancer Res Treat. 2011;130:145\u201353.","journal-title":"Breast Cancer Res Treat"},{"key":"1342_CR28","volume":"95","author":"Z Baretta","year":"2016","unstructured":"Baretta Z, Mocellin S, Goldin E, Olopade OI, Huo D. Effect of BRCA germline mutations on breast cancer prognosis: a systematic review and meta-analysis. Med (USA). 2016;95: e4975.","journal-title":"Med (USA)"},{"key":"1342_CR29","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1007\/s10549-018-5015-4","volume":"173","author":"JM Ryu","year":"2019","unstructured":"Ryu JM, Choi HJ, Kim I, Nam SJ, Kim SW, Yu J, et al. Prevalence and oncologic outcomes of BRCA 1\/2 mutations in unselected triple-negative breast cancer patients in Korea. Breast Cancer Res Treat. 2019;173:385\u201395.","journal-title":"Breast Cancer Res Treat"},{"key":"1342_CR30","doi-asserted-by":"publisher","first-page":"8545643","DOI":"10.1155\/2020\/8545643","volume":"2020","author":"K Pogoda","year":"2020","unstructured":"Pogoda K, Niwi\u0144ska A, Sarnowska E, Nowakowska D, Jagie\u0142\u0142o-Gruszfeld A, Siedlecki J, et al. Effects of BRCA germline mutations on triple-negative breast cancer prognosis. J Oncol. 2020;2020:8545643.","journal-title":"J Oncol"}],"container-title":["Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12282-022-01342-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12282-022-01342-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12282-022-01342-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,23]],"date-time":"2022-06-23T13:06:57Z","timestamp":1655989617000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12282-022-01342-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,21]]},"references-count":30,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["1342"],"URL":"https:\/\/doi.org\/10.1007\/s12282-022-01342-4","relation":{},"ISSN":["1340-6868","1880-4233"],"issn-type":[{"value":"1340-6868","type":"print"},{"value":"1880-4233","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,21]]},"assertion":[{"value":"5 October 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 February 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 February 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}